Published in JAMA on May 26, 2004
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.46
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov (2012) 2.23
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res (2007) 2.03
Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol (2012) 1.85
Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol (2004) 1.76
Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat (2010) 1.70
The impact of comorbidity on cancer survival: a review. Clin Epidemiol (2013) 1.68
NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control (2007) 1.58
Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res (2008) 1.52
COX inhibitors and breast cancer. Br J Cancer (2006) 1.27
Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol (2012) 1.27
Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer (2005) 1.21
Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2010) 1.20
Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol (2014) 1.15
Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer (2008) 1.14
The immune system and inflammation in breast cancer. Mol Cell Endocrinol (2013) 1.12
Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res (2009) 1.11
HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer (2012) 1.10
Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Arch Intern Med (2009) 1.10
Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.09
Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res (2008) 1.07
Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control (2011) 1.06
Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. Breast Cancer Res (2012) 1.04
Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res (2006) 1.01
Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control (2010) 1.01
Medication use and the risk of breast cancer. Eur J Epidemiol (2007) 0.98
Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer (2015) 0.96
Aromatase and COX in breast cancer: enzyme inhibitors and beyond. J Steroid Biochem Mol Biol (2007) 0.94
Aspirin and breast cancer prevention: the estrogen connection. JAMA (2004) 0.93
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer (2015) 0.88
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res (Phila) (2008) 0.87
Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectin. Mol Pharm (2012) 0.86
Effect of tumour necrosis factor-alpha on estrogen metabolic pathways in breast cancer cells. J Cancer (2012) 0.86
Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk: a Long Island ancillary study. Carcinogenesis (2008) 0.86
The case for developing publicly-accessible datasets for health services research in the Middle East and North Africa (MENA) region. BMC Health Serv Res (2009) 0.85
Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res (2010) 0.85
Regular aspirin use and breast cancer risk in US Black women. Cancer Causes Control (2011) 0.85
Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst (2008) 0.84
Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women. Cancer Epidemiol Biomarkers Prev (2008) 0.82
Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial. Cancer Prev Res (Phila) (2010) 0.82
Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis. Breast Cancer Res Treat (2014) 0.82
Urinary prostaglandin E2 metabolite and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2014) 0.81
Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. Breast Cancer Res Treat (2014) 0.81
Circulating levels of inflammatory markers and mammographic density among postmenopausal women. Breast Cancer Res Treat (2010) 0.81
Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst (2015) 0.81
Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Cell Death Dis (2011) 0.80
Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. Mayo Clin Proc (2015) 0.79
Aspirin and serum estrogens in postmenopausal women: a randomized controlled clinical trial. Cancer Prev Res (Phila) (2014) 0.79
A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties. BMC Cancer (2015) 0.79
Preventative therapies for healthy women at high risk of breast cancer. Cancer Manag Res (2014) 0.78
Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer. BMC Cancer (2015) 0.78
Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model. Breast Cancer Res (2008) 0.78
Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case-control study. Cancer Causes Control (2016) 0.77
Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence. Trends Pharmacol Sci (2015) 0.77
Association of aspirin use and hormone receptor status with breast cancer risk. JAMA (2004) 0.77
Modulation by aspirin and naproxen of nucleotide alterations and tumors in the lung of mice exposed to environmental cigarette smoke since birth. Carcinogenesis (2015) 0.76
Aspirin and breast cancer prevention--a link to ER status. Breast Cancer Res (2004) 0.76
Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. Breast Cancer Res Treat (2014) 0.76
Low-dose aspirin in the primary prevention of rheumatoid arthritis: the Women's Health Study. Arthritis Care Res (Hoboken) (2010) 0.75
Do early premalignant changes in normal breast epithelial cells predict cancer development? Breast Cancer Res (2004) 0.75
Association of aspirin use and hormone receptor status with breast cancer risk. JAMA (2004) 0.75
Use of acetaminophen in relation to the occurrence of cancer: a review of epidemiologic studies. Cancer Causes Control (2016) 0.75
Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. J Exp Pharmacol (2012) 0.75
The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer. Pharmaceuticals (Basel) (2010) 0.75
Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study. Breast Cancer Res (2017) 0.75
Systemic levels of estrogens and PGE2 synthesis in relation to postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev (2016) 0.75
The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives. Breast Care (Basel) (2016) 0.75
Increased temperature and entropy production in cancer: the role of anti-inflammatory drugs. Inflammopharmacology (2014) 0.75
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells. J Vis Exp (2017) 0.75
Epidemiology of gastric cancer. World J Gastroenterol (2006) 7.67
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst (2007) 4.97
Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA (2013) 4.67
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol (2010) 4.43
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst (2003) 3.71
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 3.58
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat (2010) 3.35
Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst (2003) 3.07
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol (2005) 3.02
Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) (2011) 2.97
Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci (2003) 2.91
Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev (2002) 2.83
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. Gastrointest Endosc (2011) 2.73
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell (2003) 2.71
The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat (2002) 2.71
Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol (2007) 2.69
Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol (2012) 2.59
Prenatal organophosphate metabolite and organochlorine levels and performance on the Brazelton Neonatal Behavioral Assessment Scale in a multiethnic pregnancy cohort. Am J Epidemiol (2007) 2.51
Use of the Internet by women with breast cancer. J Med Internet Res (2003) 2.46
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.41
Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer (2006) 2.36
Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev Res (Phila) (2010) 2.30
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem (2002) 2.29
Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat (2006) 2.26
Prostate cancer in fathers with fewer male offspring: the Jerusalem Perinatal Study cohort. J Natl Cancer Inst (2007) 2.24
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Persistence of multiple illnesses in World Trade Center rescue and recovery workers: a cohort study. Lancet (2011) 2.24
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov (2012) 2.23
Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol (2015) 2.22
Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol (2012) 2.21
DNA repair capacity of lymphoblastoid cell lines from sisters discordant for breast cancer. J Natl Cancer Inst (2005) 2.20
Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol (2005) 2.11
Epidemiology of upper gastrointestinal malignancies. Semin Oncol (2004) 2.10
Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol (2011) 2.10
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) (2011) 2.09
Carbonated soft drink consumption and risk of esophageal adenocarcinoma. J Natl Cancer Inst (2006) 2.08
Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila) (2009) 2.06
Electric blanket use and breast cancer on Long Island. Epidemiology (2003) 2.06
Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol (2013) 2.05
Socioeconomic and other predictors of colonoscopy preparation quality. Dig Dis Sci (2010) 2.04
Pilot study of urinary biomarkers of phytoestrogens, phthalates, and phenols in girls. Environ Health Perspect (2007) 2.04
Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia. Cancer Prev Res (Phila) (2008) 2.04
Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res (2004) 2.03
Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement use. Am J Epidemiol (2005) 2.03
The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg (2013) 2.01
Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol (2012) 1.98
A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology (2006) 1.98
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol (2005) 1.98
Fear, anxiety, worry, and breast cancer screening behavior: a critical review. Cancer Epidemiol Biomarkers Prev (2004) 1.96
Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med (2002) 1.89
Lifetime alcohol intake and breast cancer risk. Ann Epidemiol (2005) 1.85
Risk of malignancy in patients with celiac disease. Am J Med (2003) 1.85
The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev Res (Phila) (2011) 1.85
Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol (2008) 1.83
Breast cancers among very young premenopausal women (United States). Cancer Causes Control (2003) 1.80
Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer (2005) 1.78
Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys (2006) 1.77
High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. Eur Urol (2006) 1.76
Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol (2009) 1.76
Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.73
Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstet Gynecol (2013) 1.72
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Colonoscopic screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology (2008) 1.71
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) (2008) 1.71
Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer (2014) 1.71
Telomere length, oxidative damage, antioxidants and breast cancer risk. Int J Cancer (2009) 1.70
Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst (2003) 1.68
Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol (2002) 1.68
Internet use and social support in women with breast cancer. Health Psychol (2002) 1.67